Overview
- Anvisa authorized two generic registrations for liraglutide produced by EMS, a decision published on Tuesday that covers 6 mg/mL injectable solutions for subcutaneous use.
- Each generic was registered through the agency’s 'genérico — clone' pathway and is tied to an existing EMS product: one linked to Olire for obesity and the other to Lirux for type 2 diabetes.
- Approval does not mean immediate pharmacy sales because EMS must set launch dates and retail pricing, and Brazil’s drug regulator CMED caps the factory price of such generics at no more than 65% of the reference product.
- Liraglutide is a daily GLP-1 receptor agonist distinct from weekly agents like semaglutide and tirzepatide, and since 2025 all GLP-1 drugs in Brazil require a medical prescription that is retained by the pharmacy.
- The approvals increase competition in Brazil’s GLP-1 market and could affect access and costs for patients, but the real impact will depend on EMS’s commercial choices and how newer semaglutide entrants shape prices and prescribing practices.